44.68
0.06 (0.13%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | CRISPR Therapeutics AG | Bullish | Bullish |
Stockmoo Score
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Mid Core |
52 Weeks Range | ||
Price Target Range | ||
High | 100.00 (Truist Securities, 123.81%) | Buy |
Median | 94.00 (110.39%) | |
Low | 88.00 (Needham, 96.96%) | Buy |
Average | 94.00 (110.39%) | |
Total | 2 Buy | |
Avg. Price @ Call | 51.15 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Truist Securities | 12 Aug 2024 | 100.00 (123.81%) | Buy | 46.91 |
Needham | 27 Jun 2024 | 88.00 (96.96%) | Buy | 55.38 |
No data within this time range.
Date | Type | Details |
---|---|---|
05 Aug 2024 | Announcement | CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |